Press Release

Ortho Clinical Diagnostics Announces Launch of the Interleukin-6 (IL-6) Reagent Pack, Latest Addition to Ortho’s Critical Care Blood Testing Menu

Raritan, NJ

Jul 21, 2021

Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced its VITROS® Immunodiagnostic Products IL-6 Reagent Pack, the latest addition to Ortho’s VITROS® Critical Care menu, is now available in EU Countries, U.K. and several ASPAC and LATAM countries.*


Results from Ortho’s IL-6 assay can be used to help health care teams detect and evaluate inflammatory diseases, including auto-immune disorders, sepsis and cases of severe respiratory infections from COVID-19 and community-acquired pneumonia (CAP) in critically ill patients. IL-6 is gaining utility in the evaluation of the most severe forms of respiratory distress, one of the causes of poor outcomes for patients suffering inflammatory diseases. Further, Ortho’s new IL-6 assay offers earlier detection of inflammation than CRP (c-reactive protein) and is a cost-effective diagnostic complement to PCT (procalcitonin) testing, both of which help monitor the body’s inflammatory response in severely ill patients.i


“Ortho continues to bring to market solutions, like our latest IL-6 assay, that help health care teams confidently make treatment decisions sooner—especially in the critical care setting when time is of the utmost importance,” said Ivan Salgo, M.D., head of medical, clinical and scientific affairs, Ortho Clinical Diagnostics.


The performance of the VITROS IL-6 test is enhanced by the proprietary technologies and benefits only available on VITROS® Systems, building trust with performance: 


  • INTELLICHECK® Technology monitors, verifies and documents diagnostic checks throughout sample and assay processing for accurate and efficient reporting. 
  • MicroSensor Technology provides automatic hemolysis detection-quantitation; helps in managing poor quality samples; reports results faster with confidence by only flagging impacted tests.
  • MicroWell Technology combined with our enhanced chemiluminescence detection technology improves signal detection with outstanding precision and wide dynamic range.
  • Disposable Tips for samples and reagents avoids risk of false positive results caused by cross contamination. 


The IL-6 test can be run on the VITROS XT 7600 and 5600 Integrated systems, and the VITROS 3600 and ECi/ECiQ Immunodiagnostics Systems. VITROS Systems deliver consistently fast, accurate, reliable results and operational simplicity with the ability to load while running with excellent reagent/calibration stability.


Ortho’s comprehensive critical care menu also includes tests for hs Troponin, NT-pro BNP, Ferritin, CRP, D-dimer, Lactate, and PCT.


Visit Ortho’s website to learn more about our IL-6 Reagent Pack.


About Ortho Clinical Diagnostics

Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the world’s largest pure-play in vitro diagnostics (IVD) companies.


More than 800,000 patients across the world are impacted by Ortho’s tests each day. Because Every Test is a Life™, Ortho provides hospitals, hospital networks, clinical laboratories and blood banks around the world with innovative technology and tools to ensure test results are fast, accurate, and reliable. Ortho's customized solutions enhance clinical outcomes, improve efficiency, overcome lab staffing challenges and reduce costs.


From launching the first product to determine Rh+ or Rh- blood type, developing the world’s first tests for the detection of antibodies against HIV and hepatitis C, introducing patented dry-slide technology and marketing the first U.S. Food and Drug Administration-authorized high-volume antibody and antigen tests for COVID-19, Ortho has been a pioneering leader in the IVD space for over 80 years.


The company is powered by Ortho Care™, an award-winning, holistic service and support program that ensures best-in-class technical, field and remote service and inventory support to laboratories in more than 130 countries and territories around the globe.


i Niehues,T., LymphoSignJournal 5:35-47 (2018)
*Not available in the U.S.


Press contact:

For media inquiries please contact

Ortho Media Relations
Ortho Clinical Diagnostics